\-\ Texto\\:\\ \ \(0\)\
\-\ n\\/a\ \(127\)\
\-\ treatment\\ largely\\ depends\\ on\\ the\\ nature\\ and\\ severity\\ of\\ the\\ clinical\\ presentation\\.\\ \\ nonsteroidal\\ anti\\-inflammatory\\ drugs\\ \\(nsaids\\)\\ and\\ local\\ heat\\ application\\ and\\ range\\-of\\-motion\\ exercises\\ are\\ core\\ treatments\\.\\ \\ local\\ corticosteroid\\ injections\\ may\\ be\\ beneficial\\.\\ \\ needle\\ aspiration\\ or\\ surgical\\ removal\\ of\\ the\\ deposit\\ may\\ be\\ appropriate\\ in\\ patients\\ unresponsive\\ to\\ other\\ treatments\\.\ \(0\)\
\-\ ap\\ radiograph\\ of\\ the\\ left\\ shoulder\\ reveals\\ large\\ calcific\\ deposits\\ in\\ the\\ region\\ of\\ the\\ distal\\ supraspinatus\\ tendon\\,\\ the\\ most\\ common\\ site\\ of\\ hydroxyapatite\\ deposition\\.\ \(0\)\
\-\ ap\\ radiograph\\ of\\ the\\ left\\ hip\\ demonstrate\\ calcific\\ deposits\\ adjacent\\ to\\ greater\\ trochanter\\ of\\ the\\ femur\\ in\\ the\\ region\\ of\\ the\\ gluteus\\ medius\\ consistent\\ with\\ hydroxyapatite\\ deposition\\ disease\ \(0\)\
\-\ hydroxyapatite\\ deposition\\ disease\ \(2\)\
\-\ diagnosis\\ confirmed\\ by\\:\\ radiographic\\ findings\\ and\\ clinical\\ evaluation\ \(0\)\
\-\ hydroxyapatite\\ deposition\\ disease\\ \\(hadd\\)\\ associated\\ with\\:\\ \ \(0\)\
\-\ \\	hyperparathyroidism\ \(0\)\
\-\ \\	hypoparathyroidism\ \(0\)\
\-\ \\	tumoral\\ calcinosis\ \(0\)\
\-\ \\	connective\\ tissue\\ disease\ \(0\)\
\-\ \\	hypervitaminosis\\ d\ \(0\)\
\-\ \\	calcium\\ pyrophosphate\\ deposition\\ disease\\ \\(cppd\\)\ \(0\)\
\-\ \\	gout\ \(0\)\
\-\ \\	sarcoidosis\ \(0\)\
\-\ 35\\-year\\-old\\ female\\ presented\\ with\\ a\\ 10\\ year\\ history\\ of\\ shoulder\\ and\\ left\\ hip\\ pain\\.\\ \\ pain\\ was\\ worse\\ with\\ abduction\\ and\\ had\\ increased\\ substantially\\ over\\ the\\ past\\ year\\.\ \(0\)\
\-\ hydroxyapatite\\ deposition\\ disease\\ \\(hadd\\)\\ is\\ an\\ idiopathic\\ disorder\\ characterized\\ by\\ intra\\-\\ and\\/or\\ peri\\-articular\\ deposits\\ of\\ calcium\\ hydroxyapatite\\ crystals\\,\\ especially\\ in\\ or\\ around\\ the\\ tendons\\.\\ \\ the\\ shoulder\\ is\\ the\\ most\\ commonly\\ affected\\ joint\\ with\\ the\\ deposition\\ often\\ occurring\\ within\\ the\\ supraspinatus\\ tendon\\ and\\ other\\ tendons\\ of\\ the\\ rotator\\ cuff\\.\\ \\ other\\ common\\ sites\\ include\\ the\\ hip\\,\\ knee\\,\\ elbow\\ and\\ facet\\ joints\\ and\\ bursae\\ of\\ the\\ lumbar\\ spine\\,\\ though\\ hadd\\ can\\ affect\\ most\\ joints\\.\\ \\ the\\ deposits\\ are\\ often\\ monoarticular\\ in\\ distribution\\.\\ \\ \ \(0\)\
\-\ hadd\\ occurs\\ in\\ up\\ to\\ 3\\%\\ of\\ adults\\ between\\ the\\ ages\\ of\\ 40\\ and\\ 70\\ years\\ with\\ a\\ slightly\\ higher\\ frequency\\ in\\ men\\ than\\ women\\.\\ \\ clinically\\,\\ hadd\\ is\\ characterized\\ by\\ recurrent\\ episodes\\ of\\ pain\\,\\ swelling\\,\\ erythema\\,\\ and\\ tenderness\\ around\\ the\\ affected\\ joint\\.\\ \\ there\\ may\\ be\\ a\\ varying\\ degree\\ of\\ disability\\.\\ \\ some\\ patients\\ may\\ by\\ asymptomatic\\.\\ \\ \\ \ \(0\)\
\-\ the\\ natural\\ history\\ of\\ hadd\\ is\\ progressive\\,\\ although\\ all\\ stages\\ may\\ not\\ be\\ apparent\\.\\ \\ an\\ initial\\,\\ silent\\ stage\\ is\\ characterized\\ by\\ calcific\\ deposits\\ in\\ the\\ tendons\\.\\ \\ during\\ this\\ time\\ the\\ patient\\ is\\ often\\ asymptomatic\\.\\ \\ as\\ the\\ deposits\\ collect\\ they\\ increase\\ in\\ size\\ and\\ the\\ disease\\ enters\\ a\\ mechanical\\ stage\\ whereby\\ the\\ deposits\\ may\\ rupture\\ with\\ subbursal\\ or\\ intrabursal\\ extravasion\\ and\\ the\\ patient\\ may\\ experience\\ an\\ acute\\ painful\\ inflammatory\\ reaction\\ and\\ painful\\ attack\\.\\ \\ in\\ some\\ cases\\ the\\ inflammation\\ can\\ lead\\ to\\ bone\\ erosion\\,\\ adhesive\\ bursitis\\,\\ and\\/or\\ joint\\ destruction\\.\\ \\ however\\ in\\ other\\ patients\\ the\\ disease\\ has\\ resolved\\ spontaneously\\ or\\ following\\ treatment\\ with\\ nsaids\ \(0\)\
\-\ radiographically\\,\\ the\\ features\\ of\\ hydroxyapatite\\ deposits\\ depend\\ on\\ the\\ stage\\ of\\ involvement\\.\\ \\ initially\\ they\\ may\\ appear\\ as\\ amorphous\\,\\ cloud\\-like\\ densities\\.\\ \\ over\\ time\\ deposits\\ may\\ become\\ denser\\ with\\ more\\ delineated\\ borders\\ and\\ a\\ linear\\ or\\ ovoid\\ configuration\\.\\ \\ a\\ useful\\ distinguishing\\ characteristic\\ of\\ hadd\\ is\\ the\\ globular\\ appearance\\ of\\ calcium\\ deposition\\ in\\ or\\ around\\ the\\ tendons\\,\\ as\\ opposed\\ to\\ the\\ linear\\ configuration\\ of\\ calcium\\ deposition\\ in\\ within\\ the\\ cartilage\\ and\\ menisci\\ associated\\ with\\ calcium\\ pyrophosphate\\ deposition\\ disease\\.\\ \\ the\\ location\\ of\\ deposition\\ is\\ also\\ a\\ useful\\ indicator\\ of\\ hadd\\ with\\ the\\ most\\ common\\ sites\\ of\\ deposition\\ involving\\ the\\ shoulder\\ and\\ hip\\.\\ \\ \ \(0\)\
\-\ resources\\:\\ resnick\\,\\ d\\.\\ niwayama\\ g\\.\\ calcium\\ hydroxyapatite\\ deposition\\ disease\\.\\ in\\ resnick\\,\\ d\\,\\ ed\\.\\ diagnosis\\ of\\ bone\\ and\\ joint\\ disorders\\.\\ \\ 4th\\ ed\\.\\ philidelphia\\:\\ saunders\\,\\ 2002\\;\\ 1619\\-1654\\.\ \(0\)\
\-\ bonavita\\,\\ ja\\,\\ murray\\,\\ k\\,\\ et\\ al\\.\\ hydroxyapatite\\ deposition\\ disease\\.\\ \\ radiology\\ 1980\\;\\ 134\\:\\ 621\\-625\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ deposition\\:\\ 0\\.1106200996454425\ \(0\)\
\-\ hydroxyapatite\\:\\ 0\\.09562683503396216\ \(0\)\
\-\ hadd\\:\\ 0\\.0930299199303105\ \(0\)\
\-\ deposits\\:\\ 0\\.08224691063188662\ \(0\)\
\-\ calcium\\:\\ 0\\.041531020884803274\ \(0\)\
\-\ tendons\\:\\ 0\\.0344675530551144\ \(0\)\
\-\ may\\:\\ 0\\.02792873397364754\ \(0\)\
\-\ disease\\:\\ 0\\.025437273101610505\ \(0\)\
\-\ calcific\\:\\ 0\\.024990043659179985\ \(0\)\
\-\ shoulder\\:\\ 0\\.02281377745588633\ \(0\)\
\-\ hip\\:\\ 0\\.022542201139810984\ \(0\)\
\-\ characterized\\:\\ 0\\.021115083936251635\ \(0\)\
\-\ resnick\\:\\ 0\\.01980895721824597\ \(0\)\
\-\ pyrophosphate\\:\\ 0\\.019109258232592963\ \(0\)\
\-\ joint\\:\\ 0\\.018300855993656166\ \(0\)\
\-\ stage\\:\\ 0\\.018104475640372583\ \(0\)\
\-\ around\\:\\ 0\\.01767229992684793\ \(0\)\
\-\ supraspinatus\\:\\ 0\\.016975625727988615\ \(0\)\
\-\ treatments\\:\\ 0\\.016371911963770223\ \(0\)\
\-\ configuration\\:\\ 0\\.015802871377920358\ \(0\)\
\-\ sites\\:\\ 0\\.015419322319890152\ \(0\)\
\-\ nsaids\\:\\ 0\\.01526763511448852\ \(0\)\
\-\ useful\\:\\ 0\\.014764270189658632\ \(0\)\
\-\ peri\\-articular\\:\\ 0\\.014595229178752481\ \(0\)\
\-\ subbursal\\:\\ 0\\.014595229178752481\ \(0\)\
\-\ intrabursal\\:\\ 0\\.014595229178752481\ \(0\)\
\-\ extravasion\\:\\ 0\\.014595229178752481\ \(0\)\
\-\ niwayama\\:\\ 0\\.014595229178752481\ \(0\)\
\-\ 1619\\-1654\\.\\:\\ 0\\.014595229178752481\ \(0\)\
\-\ bonavita\\:\\ 0\\.014595229178752481\ \(0\)\
\-\ murray\\:\\ 0\\.014595229178752481\ \(0\)\
\-\ 621\\-625\\:\\ 0\\.014595229178752481\ \(0\)\
\-\ d\\:\\ 0\\.014111395802536283\ \(0\)\
\-\ often\\:\\ 0\\.013542087161521452\ \(0\)\
\-\ painful\\:\\ 0\\.013450093486291835\ \(0\)\
\-\ range\\-of\\-motion\\:\\ 0\\.013447634508951246\ \(0\)\
\-\ cloud\\-like\\:\\ 0\\.013447634508951246\ \(0\)\
\-\ philidelphia\\:\\ 0\\.013447634508951246\ \(0\)\
\-\ tendon\\:\\ 0\\.013202664525378136\ \(0\)\
\-\ most\\:\\ 0\\.013065133388927655\ \(0\)\
\-\ other\\:\\ 0\\.013043963898691712\ \(0\)\
\-\ local\\:\\ 0\\.012997249323658094\ \(0\)\
\-\ joints\\:\\ 0\\.01294782664082142\ \(0\)\
\-\ collect\\:\\ 0\\.012776334661090048\ \(0\)\
\-\ 134\\:\\ 0\\.012300039839150012\ \(0\)\
\-\ affected\\:\\ 0\\.012243458978641535\ \(0\)\
\-\ linear\\:\\ 0\\.01199523699694135\ \(0\)\
\-\ and\\/or\\:\\ 0\\.011958648135396367\ \(0\)\
\-\ ed\\:\\ 0\\.011958648135396367\ \(0\)\
\-\ hypoparathyroidism\\:\\ 0\\.01193059687339801\ \(0\)\
\-\ 35\\-year\\-old\\:\\ 0\\.01193059687339801\ \(0\)\
\-\ bursae\\:\\ 0\\.01193059687339801\ \(0\)\
\-\ monoarticular\\:\\ 0\\.01193059687339801\ \(0\)\
\-\ 1980\\:\\ 0\\.01193059687339801\ \(0\)\
\-\ by\\:\\ 0\\.011778732642755587\ \(0\)\
\-\ hypervitaminosis\\:\\ 0\\.011628739991288812\ \(0\)\
\-\ whereby\\:\\ 0\\.011628739991288812\ \(0\)\
\-\ nonsteroidal\\:\\ 0\\.011373523633958915\ \(0\)\
\-\ substantially\\:\\ 0\\.011373523633958915\ \(0\)\
\-\ denser\\:\\ 0\\.011373523633958915\ \(0\)\
\-\ resources\\:\\ 0\\.011373523633958915\ \(0\)\
\-\ medius\\:\\ 0\\.011152445169348778\ \(0\)\
\-\ intra\\-\\:\\ 0\\.011152445169348778\ \(0\)\
\-\ globular\\:\\ 0\\.011152445169348778\ \(0\)\
\-\ common\\:\\ 0\\.011107287476604622\ \(0\)\
\-\ patients\\:\\ 0\\.010984642049831255\ \(0\)\
\-\ calcinosis\\:\\ 0\\.010957440143427612\ \(0\)\
\-\ enters\\:\\ 0\\.010957440143427612\ \(0\)\
\-\ delineated\\:\\ 0\\.010957440143427612\ \(0\)\
\-\ deposit\\:\\ 0\\.010783002203596775\ \(0\)\
\-\ gluteus\\:\\ 0\\.010783002203596775\ \(0\)\
\-\ indicator\\:\\ 0\\.010783002203596775\ \(0\)\
\-\ \\,\\:\\ 0\\.010756691345057776\ \(0\)\
\-\ trochanter\\:\\ 0\\.010625203892662463\ \(0\)\
\-\ silent\\:\\ 0\\.010625203892662463\ \(0\)\
\-\ adhesive\\:\\ 0\\.010625203892662463\ \(0\)\
\-\ ja\\:\\ 0\\.010625203892662463\ \(0\)\
\-\ tumoral\\:\\ 0\\.010481145321487579\ \(0\)\
\-\ ap\\:\\ 0\\.010348208508749793\ \(0\)\
\-\ application\\:\\ 0\\.010225928964157681\ \(0\)\
\-\ beneficial\\:\\ 0\\.010225928964157681\ \(0\)\
\-\ crystals\\:\\ 0\\.010225928964157681\ \(0\)\
\-\ they\\:\\ 0\\.010195185849295716\ \(0\)\
\-\ depend\\:\\ 0\\.010111702355735577\ \(0\)\
\-\ or\\:\\ 0\\.00994890147977193\ \(0\)\
\-\ amorphous\\:\\ 0\\.009904478609122984\ \(0\)\
\-\ distinguishing\\:\\ 0\\.009904478609122984\ \(0\)\
\-\ bursitis\\:\\ 0\\.00980984547362638\ \(0\)\
\-\ menisci\\:\\ 0\\.00980984547362638\ \(0\)\
\-\ in\\:\\ 0\\.0097674854668271\ \(0\)\
\-\ attack\\:\\ 0\\.009635407533795541\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.00956487549005327\ \(0\)\
\-\ depends\\:\\ 0\\.009404013589465809\ \(0\)\
\-\ natural\\:\\ 0\\.009404013589465809\ \(0\)\
\-\ the\\:\\ 0\\.00938447131266334\ \(0\)\
\-\ \\:\\:\\ 0\\.00935657960257173\ \(0\)\
\-\ largely\\:\\ 0\\.009201029612491748\ \(0\)\
\-\ unresponsive\\:\\ 0\\.009201029612491748\ \(0\)\
\-\ opposed\\:\\ 0\\.00913854562576518\ \(0\)\
\-\ corticosteroid\\:\\ 0\\.009078334294356448\ \(0\)\
\-\ abduction\\:\\ 0\\.009078334294356448\ \(0\)\
\-\ g\\.\\:\\ 0\\.009020236082748384\ \(0\)\
\-\ radiograph\\:\\ 0\\.009013075012984645\ \(0\)\
\-\ anti\\-inflammatory\\:\\ 0\\.008964107685934341\ \(0\)\
\-\ cppd\\:\\ 0\\.008909819899803563\ \(0\)\
\-\ heat\\:\\ 0\\.00885725582974631\ \(0\)\
\-\ saunders\\:\\ 0\\.00885725582974631\ \(0\)\
\-\ exercises\\:\\ 0\\.00880630937500003\ \(0\)\
\-\ injections\\:\\ 0\\.00880630937500003\ \(0\)\
\-\ disability\\:\\ 0\\.00880630937500003\ \(0\)\
\-\ be\\:\\ 0\\.008726865717509464\ \(0\)\
\-\ clinical\\:\\ 0\\.00870632384127816\ \(0\)\
\-\ some\\:\\ 0\\.00859247766181046\ \(0\)\
\-\ stages\\:\\ 0\\.008487812863994307\ \(0\)\
\-\ rotator\\:\\ 0\\.008446931055069851\ \(0\)\
\-\ d\\.\\:\\ 0\\.008407034446495248\ \(0\)\
\-\ connective\\:\\ 0\\.008330014553059996\ \(0\)\
\-\ cuff\\:\\ 0\\.008292807838073143\ \(0\)\
\-\ varying\\:\\ 0\\.008292807838073143\ \(0\)\
\-\ affect\\:\\ 0\\.00815181808916535\ \(0\)\
\-\ ages\\:\\ 0\\.008021898196050292\ \(0\)\
\-\ region\\:\\ 0\\.007992057043838784\ \(0\)\
\-\ time\\:\\ 0\\.007992057043838784\ \(0\)\
\-\ men\\:\\ 0\\.007990950955963947\ \(0\)\
\-\ spontaneously\\:\\ 0\\.007990950955963947\ \(0\)\
\-\ gout\\:\\ 0\\.007930739624555212\ \(0\)\
\-\ occurring\\:\\ 0\\.007901435688960179\ \(0\)\
\-\ borders\\:\\ 0\\.007872641412947152\ \(0\)\
\-\ core\\:\\ 0\\.007844339370961554\ \(0\)\
\-\ densities\\:\\ 0\\.007844339370961554\ \(0\)\
\-\ drugs\\:\\ 0\\.00781651301613311\ \(0\)\
\-\ mechanical\\:\\ 0\\.00781651301613311\ \(0\)\
\-\ radiographically\\:\\ 0\\.00781651301613311\ \(0\)\
\-\ ovoid\\:\\ 0\\.007789146622174151\ \(0\)\
\-\ experience\\:\\ 0\\.007762225230002329\ \(0\)\
\-\ 2002\\:\\ 0\\.00773573459863405\ \(0\)\
\-\ k\\:\\ 0\\.007709661159945076\ \(0\)\
\-\ severity\\:\\ 0\\.007683991976938511\ \(0\)\
\-\ facet\\:\\ 0\\.007514656134023912\ \(0\)\
\-\ frequency\\:\\ 0\\.007469293593977365\ \(0\)\
\-\ is\\:\\ 0\\.007447559978605638\ \(0\)\
\-\ hyperparathyroidism\\:\\ 0\\.007425140867020144\ \(0\)\
\-\ cartilage\\:\\ 0\\.007361043992548803\ \(0\)\
\-\ elbow\\:\\ 0\\.007299336385268617\ \(0\)\
\-\ adults\\:\\ 0\\.007220481999524818\ \(0\)\
\-\ over\\:\\ 0\\.0072041145368872935\ \(0\)\
\-\ needle\\:\\ 0\\.007201341565085951\ \(0\)\
\-\ erosion\\:\\ 0\\.0071452131682719095\ \(0\)\
\-\ 4th\\:\\ 0\\.007126918737499418\ \(0\)\
\-\ bone\\:\\ 0\\.007031240667085662\ \(0\)\
\-\ episodes\\:\\ 0\\.006987414857337597\ \(0\)\
\-\ destruction\\:\\ 0\\.006987414857337597\ \(0\)\
\-\ erythema\\:\\ 0\\.00695430117073715\ \(0\)\
\-\ higher\\:\\ 0\\.006937989421659315\ \(0\)\
\-\ women\\:\\ 0\\.006874303526249058\ \(0\)\
\-\ resolved\\:\\ 0\\.006858757598517536\ \(0\)\
\-\ 70\\:\\ 0\\.006797993746116166\ \(0\)\
\-\ lead\\:\\ 0\\.006783144954753979\ \(0\)\
\-\ disorders\\:\\ 0\\.0067684281543943\ \(0\)\
\-\ become\\:\\ 0\\.006739381284111338\ \(0\)\
\-\ \\;\\:\\ 0\\.006706692676995344\ \(0\)\
\-\ nature\\:\\ 0\\.00669674470116032\ \(0\)\
\-\ associated\\:\\ 0\\.006677028350687755\ \(0\)\
\-\ aspiration\\:\\ 0\\.006668918346331875\ \(0\)\
\-\ appropriate\\:\\ 0\\.006668918346331875\ \(0\)\
\-\ degree\\:\\ 0\\.0066280365374074175\ \(0\)\
\-\ though\\:\\ 0\\.006562066490143842\ \(0\)\
\-\ diagnosis\\:\\ 0\\.006497415002584172\ \(0\)\
\-\ idiopathic\\:\\ 0\\.00644956539426883\ \(0\)\
\-\ reaction\\:\\ 0\\.006425570349065905\ \(0\)\
\-\ as\\:\\ 0\\.006420086949805271\ \(0\)\
\-\ can\\:\\ 0\\.006417954809500231\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.006390217493982181\ \(0\)\
\-\ distribution\\:\\ 0\\.006367061464222678\ \(0\)\
\-\ disorder\\:\\ 0\\.006355603777393914\ \(0\)\
\-\ worse\\:\\ 0\\.006266689573798117\ \(0\)\
\-\ apparent\\:\\ 0\\.006255903678067665\ \(0\)\
\-\ clinically\\:\\ 0\\.006203003678387859\ \(0\)\
\-\ femur\\:\\ 0\\.00611184510689278\ \(0\)\
\-\ lumbar\\:\\ 0\\.0060161173405205515\ \(0\)\
\-\ inflammation\\:\\ 0\\.0060161173405205515\ \(0\)\
\-\ rupture\\:\\ 0\\.00600684208298964\ \(0\)\
\-\ al\\:\\ 0\\.005997618498470675\ \(0\)\
\-\ characteristic\\:\\ 0\\.005988446014405087\ \(0\)\
\-\ site\\:\\ 0\\.005979324067698183\ \(0\)\
\-\ radiology\\:\\ 0\\.005979324067698183\ \(0\)\
\-\ recurrent\\:\\ 0\\.0059702521045117175\ \(0\)\
\-\ features\\:\\ 0\\.0059702521045117175\ \(0\)\
\-\ 40\\:\\ 0\\.005952255958424128\ \(0\)\
\-\ increase\\:\\ 0\\.005934453323032966\ \(0\)\
\-\ an\\:\\ 0\\.005869196345785082\ \(0\)\
\-\ especially\\:\\ 0\\.005823180558639837\ \(0\)\
\-\ occurs\\:\\ 0\\.005806706500935916\ \(0\)\
\-\ appear\\:\\ 0\\.005790394751858083\ \(0\)\
\-\ et\\:\\ 0\\.005790394751858083\ \(0\)\
\-\ initially\\:\\ 0\\.005758245603088046\ \(0\)\
\-\ treatment\\:\\ 0\\.005727208475499626\ \(0\)\
\-\ slightly\\:\\ 0\\.005718917646120982\ \(0\)\
\-\ progressive\\:\\ 0\\.005591786614310104\ \(0\)\
\-\ removal\\:\\ 0\\.005577452073344682\ \(0\)\
\-\ reveals\\:\\ 0\\.005535178394528184\ \(0\)\
\-\ within\\:\\ 0\\.005397786120483714\ \(0\)\
\-\ radiographic\\:\\ 0\\.005369808595676711\ \(0\)\
\-\ and\\:\\ 0\\.005364506793344258\ \(0\)\
\-\ commonly\\:\\ 0\\.005338628217641791\ \(0\)\
\-\ confirmed\\:\\ 0\\.005320198018355624\ \(0\)\
\-\ greater\\:\\ 0\\.005314099929918048\ \(0\)\
\-\ involvement\\:\\ 0\\.005185328901701683\ \(0\)\
\-\ pain\\:\\ 0\\.005183484275814908\ \(0\)\
\-\ knee\\:\\ 0\\.005129951527417676\ \(0\)\
\-\ n\\/a\\:\\ 0\\.005124514316819679\ \(0\)\
\-\ of\\:\\ 0\\.005015064272761091\ \(0\)\
\-\ involving\\:\\ 0\\.004964250437091546\ \(0\)\
\-\ location\\:\\ 0\\.004934946501496512\ \(0\)\
\-\ inflammatory\\:\\ 0\\.004906152225483483\ \(0\)\
\-\ presentation\\:\\ 0\\.004873179858428944\ \(0\)\
\-\ \\(\\:\\ 0\\.004783852491681196\ \(0\)\
\-\ although\\:\\ 0\\.004778028610226165\ \(0\)\
\-\ 10\\:\\ 0\\.004769245411170382\ \(0\)\
\-\ left\\:\\ 0\\.004748867231487987\ \(0\)\
\-\ size\\:\\ 0\\.00474317197248141\ \(0\)\
\-\ \\)\\:\\ 0\\.004725415179558312\ \(0\)\
\-\ swelling\\:\\ 0\\.004713263019836312\ \(0\)\
\-\ cases\\:\\ 0\\.004713263019836312\ \(0\)\
\-\ initial\\:\\ 0\\.0046880499060915695\ \(0\)\
\-\ spine\\:\\ 0\\.0046591118311346815\ \(0\)\
\-\ a\\:\\ 0\\.00459635531908975\ \(0\)\
\-\ past\\:\\ 0\\.004495363364149726\ \(0\)\
\-\ between\\:\\ 0\\.004484264132821596\ \(0\)\
\-\ adjacent\\:\\ 0\\.004473238814791833\ \(0\)\
\-\ during\\:\\ 0\\.004329485513118888\ \(0\)\
\-\ tenderness\\:\\ 0\\.004302834971658333\ \(0\)\
\-\ years\\:\\ 0\\.004154376054666361\ \(0\)\
\-\ evaluation\\:\\ 0\\.00410966688050796\ \(0\)\
\-\ appearance\\:\\ 0\\.004046202941613645\ \(0\)\
\-\ following\\:\\ 0\\.0040153605246707755\ \(0\)\
\-\ all\\:\\ 0\\.004001528956012071\ \(0\)\
\-\ include\\:\\ 0\\.003968797165613058\ \(0\)\
\-\ however\\:\\ 0\\.003939351085425613\ \(0\)\
\-\ history\\:\\ 0\\.003907995157970474\ \(0\)\
\-\ are\\:\\ 0\\.003857198253409277\ \(0\)\
\-\ presented\\:\\ 0\\.003856552375864916\ \(0\)\
\-\ distal\\:\\ 0\\.0038464877300430906\ \(0\)\
\-\ up\\:\\ 0\\.0038043827004208995\ \(0\)\
\-\ than\\:\\ 0\\.0037070345280103873\ \(0\)\
\-\ more\\:\\ 0\\.003538371373033388\ \(0\)\
\-\ to\\:\\ 0\\.0035353320235346547\ \(0\)\
\-\ acute\\:\\ 0\\.003493177697196184\ \(0\)\
\-\ consistent\\:\\ 0\\.003469036868925833\ \(0\)\
\-\ increased\\:\\ 0\\.003461067519535854\ \(0\)\
\-\ tissue\\:\\ 0\\.003353346338497672\ \(0\)\
\-\ 3\\:\\ 0\\.0033128733885869864\ \(0\)\
\-\ \\%\\:\\ 0\\.0033002003863344498\ \(0\)\
\-\ demonstrate\\:\\ 0\\.00325571546578318\ \(0\)\
\-\ year\\:\\ 0\\.0031659114876586582\ \(0\)\
\-\ large\\:\\ 0\\.0030936132977335755\ \(0\)\
\-\ had\\:\\ 0\\.0030527314888091194\ \(0\)\
\-\ findings\\:\\ 0\\.0030113194301158272\ \(0\)\
\-\ surgical\\:\\ 0\\.0029738771030653204\ \(0\)\
\-\ female\\:\\ 0\\.002908543495774559\ \(0\)\
\-\ patient\\:\\ 0\\.0028363971222396954\ \(0\)\
\-\ also\\:\\ 0\\.002789105287533363\ \(0\)\
\-\ has\\:\\ 0\\.0026567880306196654\ \(0\)\
\-\ on\\:\\ 0\\.0023969901071702916\ \(0\)\
\-\ with\\:\\ 0\\.0021308707566039522\ \(0\)\
\-\ there\\:\\ 0\\.0021054893318956766\ \(0\)\
\-\ not\\:\\ 0\\.0020444017744071777\ \(0\)\
\-\ \\.\\:\\ 0\\.0018219960579763817\ \(0\)\
\-\ was\\:\\ 0\\.0016362210632676934\ \(0\)\
\-\ this\\:\\ 0\\.001591286777010154\ \(0\)\
